Compositions with potentiated hypotensive effects
US4287194A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 6, 1979 |
| Grant date | Sep 1, 1981 |
| Priority date | — |
| Expiry date | Jul 6, 1999 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical compositions with hypotensive effects which comprise a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof, ##STR1## wherein R.sup.1 is formula (II) ##STR2## wherein R.sup.4 and R.sup.5 each represent hydrogen, hydroxy, nitro at the same time PA0 R.sup.2 and R.sup.3 are hydrogen, or PA0 R.sup.1 are 3-chloro-6-pyridazinylamino, 3-methyl-6-pyridazinylamino or 3-carbamoyl-6-pyridazinylamino, and at the same time PA0 R.sup.2 and R.sup.3 form together formula (III), ##STR3## wherein R.sup.6 is C.sub.1-4 alkyl group, PA0 R.sup.7 is hydrogen or a C.sub.1-4 alkyl group, and PA0 n is an integer of 1 to 3, or PA0 R.sup.2 and R.sup.3 form together a group of the general formula (IV), EQU =Q-R.sup.8 (IV) wherein PA0 Q is C.sub.5-7 cycloaliphatic, and PA0 R.sup.8 is hydrogen, a C.sub.1-4 alkoxycarbonyl or a C.sub.2-4 alkyl, and a compound of formula (V) or a pharmaceutically acceptable acid addition salt thereof, ##STR4## wherein R.sup.9 is naphthyl, 4-indolyl or 4-morpholino-1,2,5-thiadiazol-3-yl group or ##STR5## .
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.